Ivermectin for COVID-19: real-time meta analysis of 63 studies


Authors: Covid Analysis, Aug 12, 2021, Version 109 — twitter personality response, added Together Trial (V1 Nov 26, 2020) •Meta analysis using the most serious outcome reported shows 73% and 86% improvement for early treatment and…[...]

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies


Authors: Yujun Tang,† Jiajia Liu,† Dingyi Zhang, Zhenghao Xu, Jinjun Ji,* and Chengping Wen* Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) is the pathogen that causes coronavirus disease 2019 (COVID-19). As of 25 May 2020, the…[...]

Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment


Authors: Mehmet Soy 1, Gökhan Keser 2, Pamir Atagündüz 3, Fehmi Tabak 4, Işık Atagündüz 5, Servet Kayhan COVID-19 infection has a heterogenous disease course; it may be asymptomatic or causes only mild symptoms in the majority of the cases,…[...]

Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment


Authors: Philip C Robinson, Duncan Richards, Helen L Tanner, Marc Feldmann The COVID-19 pandemic continues to wreak havoc on global health-care systems and to claim an increasing number of lives.…[...]

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults


Authors: Romina Libster, M.D., Gonzalo Pérez Marc, M.D., Diego Wappner, M.D., Silvina Coviello, M.S., Alejandra Bianchi, Virginia Braem, Ignacio Esteban, M.D., Mauricio T. Caballero, M.D., Cristian Wood, M.D., Mabel Berrueta, M.D., Aníbal Rondan, M.D., Gabriela Lescano, M.D., et al., for the Fundación INFANT–COVID-19…[...]

Considerations for Certain Concomitant Medications in Patients With COVID-19


Authors: NIH Patients with COVID-19 who are receiving concomitant medications (e.g., angiotensin-converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], statins, systemic or inhaled corticosteroids, nonsteroidal anti-inflammatory drugs, acid-suppressive therapy) for…[...]